Advanced Metastatic Pancreatic Cancer

1 clinical trials · Condition

Record	Firm	Date
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients (NCT06662006)	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	2024-03-01

Every clearance here is in the API, with alerts when new ones post.